OncoSil Medical
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Industry Lists
Public Companies - non WAOncoSil Medical Limited (OSL, NeuroDiscovery Ltd) is an Australia-based and ASX-listed medical device company focused on localised treatments for patients with pancreatic and liver cancer.
OncoSil's lead product, OncoSil, is a first in class medical device with targeted radioactive isotope (Phosphorous-32) implanted directly into a patient's pancreatic tumors via an endoscopic ultrasound. This treatment, known as brachytherapy, is intended to deliver more concentrated and localized radiation.
Contact Details
Suite 402, Level 4, 50 Berry Street, NORTH SYDNEY NSW 2060
02 9223 3344
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 970th |  | OncoSil Medical | $1.5m |
| 1165th | | Firebrick Pharma | $23k |
| 1166th | | Horseshoe Metals | $21k |
| 1172nd | | Blue Star Helium | $12k |
| 1173rd | | Real Energy Corporation | $11k |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1723rd | Blue Star Helium | -68% | 9% |
| 1765th | OncoSil Medical | -72% | -44% |
| 1796th | Firebrick Pharma | -74% | |
| 1822nd | Horseshoe Metals | -77% | -5% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: Brian Leedman, Non-Executive Director | 26 Apr 2023 |
| NEWS: Tagged in Market chemistry grows biotech deals | 19 Sep 2022 |
| NEWS: Tagged in Investors turn to innovation | 19 Sep 2022 |
| NEW ROLE: Otto Buttula, Non-Executive Chair | 16 Feb 2022 |
| NEW ROLE: Ricky Sharma, Non-Executive Director | 16 Feb 2022 |
| NEW ROLE: Nigel Lange, Chief Executive, Managing Director | 14 Apr 2021 |
| REMUNERATION UPDATE: Tom Milicevic, Chief Financial Officer, Company Secretary | 03 Nov 2020 |
| REMUNERATION UPDATE: Daniel Kenny, Managing Director, Chief Executive | 03 Nov 2020 |
| REMUNERATION UPDATE: Roger Aston, Non-Executive Director | 03 Nov 2020 |
